Kim Theilgaard-Mønch

Kim Theilgaard-Mønch

Head of Research

  • Theilgaard Group

    Københavns Universitet, BRIC, Ole Maaløes Vej 5

    2200 København N

    Phone: +4535456045Mobile: +45+46708494690

Primary fields of research

Acute Myeloid Leukemia – Leukemic Stem Cells and Clinical Trials

Hematopoietic stem cells


Current research

Identification and therapeutic targeting of "oncogenic" signaling and DNA damage response pathways in preclinical models of human AML.

Novel antibody-drug conjugate therapy targeting leukemic stems cells in AML patients.

Sponsoring PI of translational exploratory investigator-initiated AML trial in collaboration with 14 Nordic AML centers. Our trial conducts extensive AML profiling including genomics, transcriptomics, phosphoproteomics, and ex vivo drug screening to identify novel effective drug combinations targeting therapy-resistant minimal residual disease/leukemic stem cells in AML patients.

Application of our novel human hematopoietic stem cell markers for (i) refinement of the human HSC phenotype and (ii) production of highly purified stem cell grafts applicable for autologous stem cell transplantation of AML and other cancer patients, as well as gene therapy of patients with monogenic diseases.

Fields of interest

Acute Myeloid Leukemia – therapeutic targeting of leukemic stem cells

Translational exploratory investigator-initiated AML trials in collaboration with the Nordic AML Group

Hematopoietic stem cells - biology and clinical application

Normal and malignant hematopoietic/myeloid development


ID: 3997971